Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the therapy.
10 United States sites
3 to 21 Years
Phase 3
The intent of this open-label, multicenter Expanded Access Program (EAP) is to provide early access to treatment with voxelotor prior to market authorization for pediatric patients age 4 to 11 years with sickle cell disease (SCD) who have no alternative treatment options and are ineligible to participate in clinical trials of voxelotor.
12 United States sites
4 to 11 Years
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies).
1 United States site
2 to 30 Years
Early Phase 1
This study seeks to utilize an innovative approach of a single session problem-solving intervention to address psychosocial factors affecting patient outcomes within the pediatric sickle cell population.
1 United States site
> 7 Years
SS
N/A
A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease .
10 United States sites
4 Tunisia sites
3 Lebanon sites
1 Greece site
1 Italy site
1 Netherlands site
1 Oman site
18 to 65 Years
HbSS
Phase 2
The purpose of the study is to assess the safety and tolerability of AG-946 in healthy volunteers after oral administration of single ascending doses (SAD) and multiple ascending doses (MAD) of AG-946 over 14 days of dosing, and to identify a range of doses that are safe and pharmacologically active in participants with sickle cell disease.
1 United States site
18 to 70 Years
Phase 1
This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102).
4 United Kingdom sites
3 United States sites
> 18 Years
Phase 2
The purpose of this research study is to compare two different ways to give opioid pain medicine to treat sickle cell disease pain that is bad enough to go to the emergency department for treatment.
6 United States sites
> 18 Years
SS, SC
Phase 3
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.
9 Brazil sites
9 United States sites
6 United Kingdom sites
5 Italy sites
5 Belgium sites
5 Germany sites
4 Spain sites
3 Netherlands sites
3 India sites
3 Greece sites
3 Colombia sites
3 France sites
2 Turkey sites
2 Canada sites
2 Panama sites
2 Lebanon sites
1 South Africa site
1 Jordan site
1 Ghana site
1 Finland site
1 Oman site
> 12 Years
Phase 3
This study aims to enroll 58 pre-adolescent (<10 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor.
11 United States sites
2 to 10 Years
Phase 2
